LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

26.58 -1.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

25.78

Максимум

26.79

Ключови измерители
By Trading Economics
Приходи	23M 7.4M
Продажби	18M 99M
EPS	0.06
Марж на печалбата	7.468
Служители	342
EBITDA	23M 11M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+19.05% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	881M 3.3B
Предишно отваряне	27.66
Предишно затваряне	26.58

Настроения в новините

By Acuity

29%

71%

72 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.02.2026 г., 23:26 ч. UTC

Значими двигатели на пазара

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10.02.2026 г., 22:31 ч. UTC

Печалби

Correction to America Movil 4Q Profit Article

10.02.2026 г., 22:22 ч. UTC

Печалби

America Movil 4Q Profit Jumps on Lower Financial Costs

10.02.2026 г., 23:51 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Печалби

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10.02.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.02.2026 г., 22:17 ч. UTC

Пазарно говорене

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10.02.2026 г., 22:15 ч. UTC

Печалби

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10.02.2026 г., 22:10 ч. UTC

Печалби

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10.02.2026 г., 22:09 ч. UTC

Печалби

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10.02.2026 г., 22:01 ч. UTC

Печалби

Intact Financial 4Q EPS C$5.24 >IFC.T

10.02.2026 г., 21:54 ч. UTC

Печалби

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10.02.2026 г., 21:53 ч. UTC

Печалби

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10.02.2026 г., 21:51 ч. UTC

Печалби

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10.02.2026 г., 21:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q EPS 12c >JHX

10.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

10.02.2026 г., 21:50 ч. UTC

Печалби

James Hardie Industries 3Q Adj EPS 24c >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

James Hardie Industries 3Q Sales $1.24B >JHX

10.02.2026 г., 21:49 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

19.05% нагоре

12-месечна прогноза

Среден 32 USD 19.05%

Висок 37 USD

Нисък 30 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

72 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.